export default function Cjc1295DacOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        CJC-1295 with DAC is a modified growth hormone releasing hormone analog engineered to last about 8 days instead of a few minutes &mdash; achieved by attaching a chemical handle that lets it bind to a naturally long-lived blood protein called albumin. One weekly injection sustains elevated growth hormone and IGF-1 for the entire week. This is the main community appeal. The tradeoff is that this is not a pulsatile, physiological growth hormone signal &mdash; it is continuous stimulation, and with an 8-day half-life, anything that goes wrong from a dose takes weeks to fully resolve. There is one meaningful human pharmacokinetic study from 2006. Long-term safety data does not exist.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Average Person &mdash; curious about growth hormone and whether this is a way to get its benefits</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I keep hearing that growth hormone declines with age and that boosting it can help with fat loss, muscle, and anti-aging. Is CJC-1295 with DAC a real way to do that, and is it safe?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The &ldquo;stimulate your own growth hormone&rdquo; framing sounds safer than injecting GH directly</strong><br />CJC-1295 with DAC doesn&rsquo;t add growth hormone to your body from outside &mdash; it tells your pituitary gland to make more of its own. That feels less interventional than synthetic growth hormone injections. The appeal is getting the benefits of elevated GH while keeping it within your body&rsquo;s own production system.</li>
          <li><strong>Once-weekly injection is genuinely convenient</strong><br />Other growth hormone-boosting peptides require daily injections, often timed precisely around sleep or meals. One injection per week that works for seven days is a substantially lower burden. For someone new to peptides who is interested in GH optimization, the once-weekly format is practical in a way that daily protocols often aren&rsquo;t.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The 8-day half-life that makes this convenient also makes it difficult to manage if something goes wrong. If you have side effects &mdash; fluid retention, numb hands, elevated blood sugar &mdash; stopping the last injection doesn&rsquo;t fix them quickly. Half the dose is still active a week after your last shot. The compound accumulates with weekly dosing over several weeks before reaching a plateau, so the experience at week one is not representative of what steady-state feels like. Growth hormone is a powerful hormone with anabolic and mitogenic properties &mdash; continuous elevation for months is not the same biological situation as your body&rsquo;s natural pulsatile GH release at night. Net: real effects, real convenience, real pharmacological commitment when you start a weekly 8-day half-life compound.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete &mdash; stacking for body recomposition and recovery</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I&rsquo;ve been running ipamorelin with no-DAC CJC-1295 and want to switch to the DAC version for convenience. What changes in practice and what should I actually watch for when I make that switch?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Continuous GH and IGF-1 elevation aligns with body recomposition goals</strong><br />Sustained elevated IGF-1 supports protein synthesis, fat mobilization, and connective tissue repair throughout the entire training week &mdash; not just in the hours following a daily injection. Athletes doing high-volume training find the sustained anabolic environment appealing. The DAC version provides this without requiring daily timing coordination with training or sleep.</li>
          <li><strong>The 2006 human study actually provides useful dose-response data</strong><br />Unlike many community peptides where human data is essentially nonexistent, the Teichman study administered CJC-1295 DAC to healthy adults and measured GH and IGF-1 responses at multiple doses. The finding that a single injection elevated IGF-1 by 30-120% above baseline for up to 14 days is real human data &mdash; not animal extrapolation. That evidence base, while limited, is more than most peptides in this space have.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Switching from no-DAC to DAC is not just switching dosing frequency &mdash; it is switching from pulsatile to continuous GH stimulation. The GH pattern matters: the body&rsquo;s physiological GH release is pulsatile (large pulses during deep sleep), and continuous elevation disrupts this pattern in ways that are not fully characterized for long-term health. Side effects that emerge at steady state (typically weeks 5-8) &mdash; carpal tunnel symptoms, water retention, insulin resistance &mdash; were manageable at first injection but amplify as the drug accumulates. Athletes with any family history or personal risk for cancer should note that sustained continuous IGF-1 elevation represents a different mitogenic stimulus than pulsatile. Net: legitimate performance tool with real evidence, but the steady-state accumulation pharmacology requires more active monitoring than the daily peptide stack it often replaces.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Biohacker &mdash; optimizing GH axis signaling and understanding DAC pharmacokinetics</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I want to understand the DAC chemistry &mdash; the maleimide-thiol reaction with albumin Cys34 &mdash; and think through how the albumin-bound peptide complex interacts with pituitary GHRH receptors given that albumin doesn&rsquo;t cross the blood-brain barrier. What is the actual delivery mechanism?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The albumin conjugation chemistry is an elegant half-life engineering solution</strong><br />The DAC modification adds a maleimidoproprionic acid linker that reacts with the free thiol of Cys34 on circulating albumin &mdash; the only free cysteine in albumin&rsquo;s structure. The resulting covalent thioether bond is stable in circulation. Because albumin has a 19-day half-life (maintained by FcRn recycling that protects albumin from lysosomal degradation), the CJC-1295-albumin complex is cleared at albumin&rsquo;s rate rather than the peptide&rsquo;s intrinsic rate. The GHRH receptor-activating sequence of CJC-1295 is presented on the albumin surface &mdash; and because pituitary fenestrated capillaries allow albumin passage, the albumin-bound CJC-1295 can activate pituitary GHRH receptors through this fenestrated endothelium even though it cannot cross a continuous blood-brain barrier.</li>
          <li><strong>Pulsatile vs. continuous GH is a meaningful mechanistic distinction for optimization</strong><br />The GH axis has receptor desensitization dynamics: continuous GHRH receptor stimulation can downregulate pituitary GHRH receptor expression over time, potentially blunting the GH response at steady state. The 2006 Teichman trial showed GH responses were sustained over the study duration, but that was a short-term pharmacokinetic study rather than a chronic tolerance assessment. Biohackers interested in GH axis optimization need to think about GHRH receptor desensitization, somatostatin feedback, and whether cycling CJC-1295 DAC is pharmacologically justified.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The pharmacokinetic elegance of DAC chemistry does not translate to validated long-term safety. The 2006 Teichman study provides excellent short-term PK/PD data but is not a long-term safety study. The continuous IGF-1 elevation at steady state &mdash; 30-120% above baseline for months in community protocols &mdash; represents an anabolic and mitogenic environment that is not the same as normal physiological aging or even therapeutic GH replacement at physiological levels. GHRH receptor desensitization, somatostatin rebound after stopping, and the downstream effects of sustained IGF-1 on insulin sensitivity are areas where community use is running ahead of human evidence. The DAC modification site (Cys34 on albumin) is also a site for endogenous albumin modifications from reactive metabolites &mdash; the in-vivo binding competition and occupancy at different doses in humans has not been characterized. Net: mechanistically sophisticated compound with excellent short-term PK data, genuine unknowns at steady-state and chronic dosing, and cancer contraindication that applies more strongly than for shorter-acting GHRH analogs due to the sustained continuous IGF-1 elevation.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What CJC-1295 with DAC is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>Interchangeable with no-DAC CJC-1295 at the same dose &mdash; the 8-day half-life creates fundamentally different pharmacology</li>
              <li>Quickly reversible if side effects develop &mdash; stopping the injection does not clear the compound for 2-4 weeks</li>
              <li>A pulsatile growth hormone stimulus &mdash; it produces continuous GH elevation, not the physiological pulsatile pattern</li>
              <li>Appropriate for anyone with cancer history &mdash; sustained continuous IGF-1 elevation is a stronger mitogenic stimulus than shorter-acting alternatives</li>
              <li>Supported by long-term human safety data &mdash; the 2006 study is short-term PK, not a chronic safety study</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>The DAC albumin-binding chemistry is a genuine pharmacological innovation for extending peptide half-life</li>
              <li>One meaningful human study with actual dose-response and PK data &mdash; more evidence than most community peptides have</li>
              <li>Once-weekly dosing is a real practical advantage for people who tolerate continuous GH elevation</li>
              <li>The pulsatile vs. continuous GH debate is an interesting physiological question with practical implications for how this compound compares to shorter-acting alternatives</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
